Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Chronic noncancer pain is now considered a global epidemic and a public health problem in the United States, partly owing to its prevalence, underdiagnosis, and undertreatment.
Clinical Assessment of Abuse-Deterrent Formulations
Ofer M. Wellisch, MD, MPH
Read More
In Vitro and Clinical Assessments of Abuse-Deterrent Formulations for Chronic Pain
Sabby Muneer, PhD
Read More
In Vitro and Clinical Assessments of Abuse-Deterrent Formulations in the Management of Chronic Pain
Gary M. Owens, MD
Read More
The Tip of the Iceberg
Atheer A. Kaddis, PharmD
Read More
Results 1 - 4 of 4